This fantastic presentation by Dr. John Carmichael, Distinguished Professor of Clinical Medicine at the University of Southern California and Co-director of the USC Pituitary Center focuses on the controversies arising from the clinical dilemmas present in treating a complicated condition like acromegaly.
Acromegaly
Acromegaly is usually caused by a noncancerous tumor. Middle-aged adults are most commonly affected. Symptoms include enlargement of the face, hands, and feet. Prompt treatment is needed to avoid serious illness. Drugs can reduce the effects of growth hormone. If needed, surgery and radiation may be used to remove tumor cells.
The ride for acromegaly
From Jorge D. Faccinetti – co-founder. With a pituitary disease like acromegaly, Cushing’s, hypopituitarism, and others, or for that matter, any other chronic condition, a big part of the battle is to get up every
Two clinical trials for acromegaly patients: see if you are eligible.
Camurus AB, a pharmaceutical company based in Lund, Sweeden, is currently recruiting volunteers for two clinical trials on the long-term safety and efficacy of an octreotide subcutaneous depot to treat acromegaly. This new treatment offers
Ionis Rare Disease Webinar series on Acromegaly
If you missed this fantastic event, here is an on-demand video you can watch at your leisure. In this second installment of the Ionis’ Rare Disease Webinar series, panelists discuss acromegaly, a condition in which
PFDD: an excellent opportunity for acromegaly patients to get involved
On Thursday, January 21, 2021, there is a virtual FDA Externally Led Patient-Focused Drug Development (PFDD) meeting organized by the Acromegaly Community, a leading patient advocacy organization in the US. To learn more about
A talk with Crinetics Chairman Scott Struthers, Ph.D.
During these trying times, work continues, even at a faster pace, for new drugs and therapies for pituitary patients. From the J D Faccinetti, co-founder – We recently caught up with Crinetics Pharmaceuticals chairman Dr.
A discussion on telemedicine and pituitary disease
Important changes in telehealth visit regulations provide an excellent opportunity for patients to receive consultations from highly experienced specialists in pituitary disease. Read on! On Monday, November 16, 2020, doctors Lewis Blevins and Sandeep Kunwar
On November 1 organizations around the world mark Acromegaly Day
Patients, advocacy, and healthcare organizations are promoting awareness of the condition around the world. The World Alliance of Pituitary Organizations WAPO Board decided to re-use the WAPO Acromegaly Awareness Campaign of 2019 to raise awareness on
A note on the importance of awareness
Tell us what is like to live with acromegaly From J D Faccinetti – co-founder and chief editor: In the awareness business, coming up with new, fresh, creative ideas is essential to get your message across,
Day time TV tackles acromegaly
Pituitary World News’ main goal is to increase awareness of pituitary disease so more people are diagnosed early and properly. So when a daytime TV program, “The Balancing Act airing on Lifetime TV, tackles the
A tale of two patients: the biology of different pituitary tumors
Two patients with residual pituitary tumors and their unpredictable differences.
Hello, Pills!
With the recent approval and commercial launch of MYCAPSSA®, Chiasma delivers the first and only oral somatostatin analog to treat acromegaly. The research showed 58% of patients maintained normal IGF-1 levels with the new oral
A personal story
From Risa Heidt, triathlete, ironwoman – Marshmallow Clouds – It was September 2018. In preparation for my next big cycling event, a 100-mile Century ride in New Mexico, I rode 50 miles a day for weeks